Public Funding for Oxford Heartbeat Ltd

We have developed PreSize medical device software: novel clinical decision-support that helps surgeons plan and rehearse implant placements inside blood vessels with realistic simulations right before starting life-saving surgery. Using cutting-edge computational modelling, we use patient imaging and ultra-realistic implant mechanics to accurately predict implant behaviour inside each patient's vessel anatomy. This allows clinicians to select the best implant for every patient, reducing complications and cost of surgeries. This project develops PreSize Surgery. This solution will allow clinicians to not only accurately plan surgical procedures, but also accurately execute them. It will enable PreSize's high-accuracy modelling power to be translated into accurate, efficient and effective implant deployments. Specifically, it will provide clinicians with never-before-seen precise and real-time intelligence about the destination and progress of live implantation on the low-quality biplane images that they rely on for guidance of these live minimally invasive procedures. We are an award-winning start-up formed to bring this novel technology to hospitals. With a strong team of engineering, software, commercial, legal and regulatory experts, we have been previously supported by Innovate UK (IUK) and the National Institute for Health and Care Research (NIHR) and receive ongoing support from The Royal Academy of Engineering. Our awards include: * IUK's 'Women in Innovation' Award 2023 for 'one of 50 of the UK's leading women entrepreneurs for game-changing ideas' * BioMedEng Innovation Prize 2021 for 'ground-breaking work which has led to new technologies that support medical interventions' * AI in Health and Care Award from NIHR and NHS (2020) * "Best UK Healthcare Start-up of 2018"(WIRED magazine) * NHS Innovation Award 2017(Health Enterprise East) We were selected for the DigitalHealth.London Accelerator programme and were one of 6 startups selected globally by Philips Healthcare Accelerator. We have been featured in the general press: * PreSize was captured in action on 'BBC Click' tech show(February 3 2023, BBC iPlayer), * Our ground-breaking "Man vs Machine" study was covered by multiple media outlets, including: Sky News("AI-driven software could revolutionise brain aneurysm treatment"), Independent, Evening Standard(October 2023), * In The Times article "Why Britain is the premier location for AI companies"(August 2023), * Forbes("Founders striving to change the world"), * WIRED("From AI doctors to 3D X-rays, the future of healthcare is already here"), * Also: Financial Times, The Telegraph. We aim to grow Oxford Heartbeat to become the leading provider of clinical decision-support tools, boost the UK economy and its international leadership in healthcare, improve healthcare for all, and define the medicine of tomorrow.

We have developed PreSize medical device software: a novel clinical decision-support solution that helps surgeons plan and rehearse implant placements inside brain blood vessels with realistic, real-time simulations right before starting life-saving surgery. Using cutting-edge computational modelling, we make best use of patient imaging and device mechanics to accurately predict device behaviour inside each patient's vessel anatomy. This allows clinicians to select the best device for every patient, reducing complications and cost of surgeries for hospitals/society. This project will extend/increase PreSize's power to support crucial clinical decision-making for more patients, across their journey from diagnosis to treatment. We will provide never-before-seen capabilities to clinicians and potential for aneurysm care pathways to be radically transformed. Specifically, we will advance the already ground-breaking PreSize to support diagnostic **CTA** scans(rapid, inexpensive, minimally-invasive imaging used for most patients suspected of aneurysm) in addition to (3D)**DSA** that PreSize currently uses(expensive, invasive imaging, but of significantly higher quality; used to guide placement of implant during procedure). **Proposed PreSize Diagnostic** adds Precision Medicine throughout the care pathway instead of only on surgery day, supporting patient-specific treatment stratification/planning and helping clinicians best prepare for surgery day (accommodating best implant choices and delivering best surgical outcomes) with unprecedented technological support. These technological advancements ultimately aim to reduce patient suffering, minimise healthcare costs, and optimise/standardise care. We are an award-winning start-up created to bring this novel technology to hospitals. With a strong team of engineering, software, commercial, legal and regulatory experts, we have been previously supported by IUK and NIHR and receive ongoing support from The Royal Academy of Engineering. Our awards include: * NHS Innovation Award 2017 * "Best Healthcare Start-up of 2018" (WIRED) * BioMedEng Innovation Prize 2021 for 'ground-breaking work which has led to new technologies that support medical interventions' * **IUK's 'Women in Innovation' Award 2023** for 'one of 50 of the UK's leading women entrepreneurs for game-changing ideas' We were selected for the DigitalHealth.London Accelerator programme, and were one of 6 startups selected globally by Philips Healthcare Accelerator. We have featured in the general press, e.g., Forbes, WIRED, The Times, Financial Times, The Telegraph, etc. Most recently, PreSize was captured in action in the **BBC Click** tech show (February 3, 2023, BBC iPlayer).We aim to grow Oxford Heartbeat to become the leading provider of clinical decision-support tools, to boost the UK economy and its international leadership in healthcare, to improve healthcare for all, and define the medicine of tomorrow.

I am a CEO of Oxford Heartbeat (OxHB) - mission-driven medical technology startup. I am also an Enterprise Fellow of The Royal Academy of Engineering, a PhD in Biomedical Engineering from University of Oxford, MSc in Computer Science from Humboldt University of Berlin (minor in Business) and was previously Researcher in AI at Sony in Paris. I was named a "founder striving to change the world" by Forbes and recently awarded the BioMedEng Innovation Prize for "imaginative and ground breaking work that led to new technologies supporting medical interventions." After obtaining a PhD and having witnessed the shortcomings of the status quo in surgery, I founded OxHB to translate my academic research to clinical practice. I am both CEO and CTO of the company, which has developed innovative AI software PreSize Neurovascular allowing surgeons to simulate placement of stent implants within blood vessels so they can more safely and effectively treat cardiovascular diseases, defining a new standard of surgical planning. We have achieved CE-marking and ISO13485-certification and are now running a UK-wide clinical trial to collect evidence of its impact in clinical practice, funded by the UK Government's prestigious AI in Health and Care Award and NIHR. The Women In Innovation Award will support our preparations for scale up and internationalisation - the critical next step to grow our business and become global players.The award's non-financial support, i.e., expert advice on scaling up, sales and negotiations skills and building new business models, will contribute to our timely preparation for expansion of our business globally, thus helping OxHB enter a new stage of its journey. Success of this project would be seeing our efforts, supported by this award, flourishing into commercial engagements, and importantly, benefitting many patients' lives. Results from our previous projects received numerous awards, including NHS Innovation Award 2017 (HEE), WIRED "Best UK Healthcare Start-up of 2018", and our PreSize technology has been recently featured in The Times (6 September 2021).

Our goal is to make cardiovascular surgeries more efficient and safe. This project increases the power of our PreSize medical device software - a novel clinical decision-support solution that helps surgeons plan and rehearse implant placements inside blood vessels with realistic surgery simulations. Using cutting-edge computational modelling, we make the best use of available patient scans and device mechanics to accurately predict the behaviour of devices inside each patient's vessel anatomy. This allows clinicians to select the best device for every patient, reducing the number of complications and associated cost of surgeries for hospitals and our society. What is especially innovative with this project is that the PreSize platform will be developed to be as easily accessible as possible, aimed to maximise its reach and benefits across the healthcare system. We are an award-winning start-up company specifically created to bring this technology to hospitals. With a strong team of engineering, software, commercial, legal and regulatory experts, we have been previously supported by Innovate UK grants (currently running BMC Early Stage award until April 2022) and receive ongoing support by The Royal Academy of Engineering. The results of our previous projects have received numerous awards, including: * NHS Innovation Award 2017 from Health Enterprise East (HEE) * "Best Healthcare Start-up of 2018" by WIRED magazine * BioMedEng Innovation Prize 2021 for recognition of our founder's 'ground-breaking work which has led to new technologies that support medical interventions' We were also selected to be part of the Digital Health London Accelerator programme, and were previously one of the 6 startups selected globally by Philips Healthcare Accelerator, as well as featured in the general press, e.g., in Forbes ("Founders striving to change the world") and WIRED ("From AI doctors to 3D X-rays, the future of healthcare is already here"), as well as The Times, Financial Times, The Telegraph, etc. Our aim is to grow Oxford Heartbeat to become the leading provider of clinical decision support tools, to boost the UK economy and its international leadership in healthcare, to improve healthcare for all, and define the medicine of tomorrow.

Our goal is to make cardiovascular surgeries more efficient and safe. This project develops the PreSize platform, a novel clinical decision-support solution that helps clinicians plan and rehearse stent placements inside blood vessels. Using cutting- edge computational modelling, we make the best use of available patient scans and stent device mechanics to accurately predict the behaviour of devices inside each patient's vessel configuration. This allows clinicians to optimise device selection, reducing the number of complications and the associated cost of stenting surgeries for hospitals and our society. We are a start-up company specifically created to bring this technology to hospitals. We currently run IUK Biomedical Catalyst Primer (BMC-P) project, and are incubated by The Royal Academy of Engineering. The results of our previous projects have received numerous awards, including the NHS Innovation Award 2017 from Health Enterprise East (HEE). We were named the "Best Healthcare Start-up of 2018" by WIRED magazine and were the national winner at the prestigious Medilink UK Healthcare Business Awards 2017\. We were selected to be part of the Digital Health London Accelerator (DHLA) programme, and previously one of the 6 startups selected globally by Philips Healthcare Accelerator, as well as featured in two Forbes articles as "founders striving to change the world" and "one of the new British start- ups to watch closely", two WIRED articles: "These are the healthcare start-ups you need to know about" and "From AI doctors to 3D X-rays, the future of healthcare is already here", and have been featured in The Times, Financial Times, etc. Our aim is to grow Oxford Heartbeat to be the leading provider of clinical decision support tools, to improve healthcare and define the medicine of tomorrow.

Our goal is to make cardiovascular surgeries more efficient and safe. This project develops the PreSize platform, a novel clinical decision-support solution that helps clinicians plan and rehearse stent placements inside blood vessels. Using cutting-edge computational modelling, we make the best use of available patient scans and stent device mechanics to accurately predict the behaviour of devices inside each patient's vessel configuration. This allows clinicians to optimise device selection, reducing the number of complications and the associated cost of stenting surgeries for hospitals and our society. We are a start-up company specifically created to bring this technology to hospitals. We currently run IUK Biomedical Catalyst Primer (BMC-P) project, and are incubated by The Royal Academy of Engineering. The results of our previous projects have received numerous awards, including the NHS Innovation Award 2017 from Health Enterprise East (HEE). We were named the "Best Healthcare Start-up of 2018" by WIRED magazine and were the national winner at the prestigious Medilink UK Healthcare Business Awards 2017\. We were selected to be part of the Digital Health London Accelerator (DHLA) programme, and previously one of the 6 startups selected globally by Philips Healthcare Accelerator, as well as featured in two Forbes articles as "founders striving to change the world" and "one of the new British start-ups to watch closely", two WIRED articles: "These are the healthcare start-ups you need to know about" and "From AI doctors to 3D X-rays, the future of healthcare is already here", and have been featured in The Times, Financial Times, etc. Our aim is to grow Oxford Heartbeat to be the leading provider of clinical decision support tools, to improve healthcare and define the medicine of tomorrow.

no public description

"Our goal is to make cardiovascular surgeries more efficient and safe. This project develops the PreSize Stenting Platform, a novel solution that helps clinicians plan and rehearse stent placements inside blood vessels. Using cutting-edge computational modelling, we make the best use of available patient scans and stent device mechanics to accurately predict the behaviour of devices inside each patient's vessel configuration. This allows clinicians to optimise device selection, reducing the number of complications and the associated cost of stenting surgeries for hospitals and our society. We are a start-up company specifically created to bring this technology to hospitals. We are currently incubated by The Royal Academy of Engineering. The results of our previous projects have received numerous awards, including the NHS Innovation Award 2017 from Health Enterprise East (HEE). Oxford Heartbeat was also the national Winner at the prestigious Medilink UK Healthcare Business Awards 2017, the Finalist of Pitch@Palace organised by His Royal Highness The Duke of York and was recently named the ""Best Healthcare Start-up of 2018"" by WIRED magazine. We were also featured in two Forbes articles as ""founders striving to change the world"" and ""one of the new British start-ups to watch closely"", and two WIRED articles: ""These are the healthcare start-ups you need to know about"" and ""From AI doctors to 3D X-rays, the future of healthcare is already here"", as well as in The Times, Financial Times, etc. Our aim is to grow Oxford Heartbeat to be the leading provider of clinical decision support tools, to improve healthcare and define the medicine of tomorrow."

Stenting is a popular treatment for common cardiovascular diseases, such as aneurysms or stenosis, performed in hospitals on a daily basis. Stents are small metallic tubes surgically placed inside diseased blood vessels to provide vascular support or relieve obstructions. Although, stenting is becoming more and more popular due to its minimally-invasive nature, there are a number of challenges associated with successful stent delivery. For a successful surgery, choosing the correct device is critical. Considering the significant anatomical variations between patients and differences in device mechanics, it is currently extremely difficult to predict the final configuration of a stent after deployment. This results in high mortality and morbidity, dangerous complications, increased cost, and the need for secondary surgeries. In the proposed project we will be investigating the desirability and usefulness to clinicians of a novel knowledge repository which they can consult in preparation of surgeries. Working together with designers, we will be using the human-centred Idea's Design Kit methodology. During the immersion phase in hospital environment, we will be conducting in-depth research with end users -- neurosurgeons/interventional neuroradiologists -- to determine their needs and design a proposed solution. Thereafter, the initial prototype sketches will be user-tested in the series of interviews and the received feedback used to iteratively improve the proposed solution to ensure it is fully aligned with clinical needs and to facilitate future adoption. This functionality would provide unprecedented all-encompassing support for surgical preparation, improving patient outcomes and providing peace of mind to clinicians.

"Oxford Heartbeat (OxHB) is an early-stage start-up developing innovative technology to make cardiovascular surgeries more efficient and effective. We are building software that helps surgeons plan and rehearse minimally invasive stent placements inside blood vessels -- currently the most popular treatment for common cardiovascular disorders. The software allows surgeons to simulate how different stents will fit and behave in a patient's anatomy and select the best surgical scenario for every patient. The software will be installed in hospitals and used in surgery preparation, reducing the number of complications and the associated cost to hospitals and society. Having developed the minimal viable product for placements of cerebral stents in the brain, the next stage is to validate the accuracy of our simulated results. Since we are operating within the domain of surgery, it is paramount that the technology delivers highly accurate results to reliably support clinical decision-making. Therefore, we need to compare the results of our simulations with real clinical outcomes. To enable comparison to our simulations, we need to measure the configurations of real stent devices that have been deployed inside patients using clinically available historic 2D scans -- solving this complex measurement problem is the focus of this project. In the proposed project we aim to develop and evaluate a novel methodology for obtaining accurate measurements of the size and position of the complex 3D shape of stents inside brain blood vessels from the 2-plane projection view of the patient's brain captured by X-ray angiography. The expertise in accurate measurements and uncertainty quantifications will be provided by the National Physical Laboratory(NPL). The main activities include developing the new method for measuring the reference configuration of the stent from 2D patient scans by aligning them with preoperative anatomy (constructed in our software) using the metadata stored in the scans. We will test out potential steps to achieve accurate alignment and measurements in a synthetic model, then transfer it to real anonymised clinical images and, finally, perform uncertainty analysis for the main variables. The proposed project builds upon the successfully completed IUK SMART Proof of Market(PoM, 2016), Biomedical Catalyst Feasibility (BMC-F, 2017), as well as funding from NIHR i4i Connect and SBRI Healthcare (2018). The results of our previous projects have received numerous awards, including the NHS Innovation Award 2017(HEE). Oxford Heartbeat was also named the UK Start-up of 2017 at Medilink UK and the WIRED ""Best Healthcare Start-up of 2018."""

Our goal is to make cardiovascular surgeries more efficient and safe. We propose to develop technology that helps clinicians to accurately plan and rehearse stent placements inside blood vessels. Using cutting-edge computational modelling, we make maximum use of available patient data and device mechanics to accurately predict the behaviour of devices inside each patient’s vessel configuration. This allows clinicians to optimise the device selection, thereby reducing complications and associated cost of stenting surgeries for hospitals and society.

This project aims to validate the requirements and market potential of a software tool for surgeons to assist their decision making process and enable improvements in quality of care, efficiency and treatment outcomes.